Cadonilimab plus chemotherapy compared to chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer in China: a cost-effectiveness analysis

Abstract Objective To assess the cost-effectiveness of cadonilimab plus chemotherapy compared to chemotherapy alone as first-line treatment for metastatic cervical cancer from the Chinaese medical healthcare perspective. Methods We developed a partitioned survival mode to simulate the costs and outc...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Longfeng Zhang, Qingsheng Yang, Huide Zhu, Zhiwei Zheng
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-12-01
coleção:	BMC Health Services Research
Assuntos:	Cost-effectiveness analysis Cadonilimab Chemotherapy Metastatic cervical cancer Quality-adjusted life year Incremental cost-effectiveness ratio
Acesso em linha:	https://doi.org/10.1186/s12913-025-13871-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!